secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2023-10-24T23:59:59+00:00
Accession:  0001193125-23-261221
Event type: other
Sentiment:  neutral
Materiality: 0.30
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aeglea BioTherapeutics posts corporate presentation showing anti-TL1A antibody SPY002 with picomolar potency
--------------------------------------------------------------------------------

- Non-clinical data for SPY002 (anti-TL1A antibody) show monomer and trimer binding at picomolar potencies.
- Corporate presentation posted on October 24, 2023, includes updates on research pipeline.
- No new financial results, guidance, or material operational changes disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000119312523261221/0001193125-23-261221-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000119312523261221/d496165d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-261221

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer